港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

496.720

-5.792-1.15%

漲家數：6

跌家數：25

平家數：2

市盈率：- -

高：507.303

開：502.573

低：495.158

收：502.512

成交量：8,175.03萬

成交額：18.06億

市值：3,152.73億

流通市值：2,806.09億

資料載入中...

總覽新聞資訊

貝康醫療-B(02170.HK)：GEMS系列玻璃化冷凍液及解凍液套裝獲國家藥監局頒發三類醫療器械註冊證

蘇州貝康醫療-B：Gems玻璃化冷凍及復甦套裝獲NMPA三類醫療器械註冊證

康為世紀(688426.SH)：艱難梭菌tpi和毒素A、毒素B基因檢測試劑盒(熒光PCR法)獲三類醫療器械註冊證

康寧傑瑞製藥-B(09966)9月15日斥資96.7萬港元回購12.2萬股

凌愈製藥高端複雜注射劑項目奠基：攻堅「製劑皇冠明珠」，「中國製造」劍指全球市場

科華生物(002022.SZ)：兩款產品獲得醫療器械註冊證

董事長兼總裁吳豫生增持同源康醫藥-B(02410.HK)40萬股每股作價約2.82港元

創新藥「一日遊」？華寶基金藥ETF、港股通創新藥ETF雙雙回調！基本面仍有支撐：數據讀出+出海邏輯持續驗證

全球首個！上海交大教授創辦，AI製藥拿下C1輪融資

勁方醫藥-B(02595)9月15日斥資129.56萬港元回購5萬股

歸創通橋(02190)9月15日耗資約112.75萬港元回購5.5萬股

交銀國際：維持德琪醫藥(06996.HK)「買入」評級目標價10港元

可以多活8.2個月！國產雙抗挑戰全球腫瘤「藥王」總生存期勝出

港股異動 | 心瑋醫療-B(06609)升逾5% 上半年缺血性卒中業務收入持續穩增公司穩步推進A股IPO進程

港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准

禮邦醫藥－Ｂ(09637)股價顯著上升14.696%，現價港幣$26.38

阿斯达克财经

渠道紅利見頂，主動投研掉隊工銀瑞信的權益短板誰來補？

同源康醫藥－Ｂ(02410)股價大幅上升15.635%，現價港幣$3.55

阿斯达克财经

浙商證券：醫療器械子版塊多因素交織低值耗材板塊表現亮眼

港股異動 | 同源康醫藥-B(02410)漲逾10% 大股東增持提振市場信心此前核心品種已順利獲批

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":496.71994,"timestamp":1789459707407,"preClose":502.51205,"halted":0,"volume":81750325,"delay":0,"changeRate":-0.011526,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":-5.792114,"latestTime":"09-15 16:00:00","open":502.57327,"high":507.303,"low":495.15784,"amount":1806018702,"amplitude":0.024169,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789522200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789435800000,1789444800000],[1789448400000,1789459200000]],"pbRate":3.744174,"peRate":166.585651,"turnoverRate":0.00304,"increases":7,"decrements":24,"flats":1,"marketCap":315273116400,"floatMarketCap":280608949080},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":507.303,"amplitude":0.024169,"preClose":502.51205,"low":495.15784,"pbRate":"3.744174","latestPrice":496.71994,"volume":81750325,"delay":0,"open":502.57327,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":518.573,"twentyDayClose":502.603,"sixtyDayClose":431.958,"secType":"PLATE","market":"HK","turnoverRate":0.00304,"peRate":166.585651,"marketCap":315273116400,"floatMarketCap":280608949080,"timestamp":1789459707407,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667400546","title":"貝康醫療-B(02170.HK)：GEMS系列玻璃化冷凍液及解凍液套裝獲國家藥監局頒發三類醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2667400546","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667400546?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 21:46","pubTimestamp":1789479966,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09996","BK1583","BK1597","02170","BK1222","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117355886","title":"蘇州貝康醫療-B：Gems玻璃化冷凍及復甦套裝獲NMPA三類醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=1117355886","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117355886?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 21:45","pubTimestamp":1789479939,"startTime":"0","endTime":"0","summary":"苏州贝康医疗-B宣布，其Gems玻璃化冷冻及复苏套装已正式获得国家药品监督管理局颁发的三类医疗器械注册证书。这一里程碑式的进展，标志着该公司在辅助生殖技术领域的又一次重要突破。据悉，此次获批的Gems系列产品，专为胚胎和卵子的冷冻保存及解冻复苏环节精心打造。未来，贝康医疗将持续深耕辅助生殖全产业链，力求以更具创新性的产品矩阵，满足多元化的临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02170","BK1574","BK1222","BK1597"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644048","title":"康為世紀(688426.SH)：艱難梭菌tpi和毒素A、毒素B基因檢測試劑盒(熒光PCR法)獲三類醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644048","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644048?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 20:04","pubTimestamp":1789473869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康为世纪 发布公告，近日，公司全资子公司江苏健为诊断科技有限公司自主研发的艰难梭菌tpi和毒素A、毒素B基因检测试剂盒获得国家药品监督管理局颁发的Ⅲ类《医疗器械注册证》。该产品通过对粪便样本中tpi、tcdA及tcdB基因的同步检测，辅助临床诊断艰难梭菌感染。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496441.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","MDEV","IEIH","LNGR","688426","BK0239","HART","LGHT","PCR","MEDX","AGNG","159883","PTH","GDOC","09996","RSPH","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667644517","title":"康寧傑瑞製藥-B(09966)9月15日斥資96.7萬港元回購12.2萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667644517","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667644517?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:44","pubTimestamp":1789472658,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布公告，于2026年9月15日斥资96.7万港元回购12.2万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496420.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09966","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667564486","title":"凌愈製藥高端複雜注射劑項目奠基：攻堅「製劑皇冠明珠」，「中國製造」劍指全球市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2667564486","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667564486?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:34","pubTimestamp":1789472040,"startTime":"0","endTime":"0","summary":"9月15日，浙江凌愈制药有限公司高端复杂注射剂项目奠基仪式在浙江台州举行。复杂注射剂被誉为“制剂工业皇冠上最难摘的明珠”，涵盖微球、脂质体、长效缓释制剂等前沿剂型，是医药产业迈向全球价值链高端的关键突破口。凌愈制药由海正药业与圣兆药物于2025年12月合资组建。本次项目奠基，不仅是一座工厂的破土动工，更是国产高端复杂注射剂跻身全球高端制剂市场的郑重宣言。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-15/doc-inirxhzq8487339.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667450641","title":"科華生物(002022.SZ)：兩款產品獲得醫療器械註冊證","url":"https://stock-news.laohu8.com/highlight/detail?id=2667450641","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667450641?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:18","pubTimestamp":1789471138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科华生物(002022.SZ)发布公告，近日，公司及公司控股子公司苏州天隆生物科技有限公司(以下简称“苏州天隆”)收到国家药品监督管理局颁发的医疗器械注册证(体外诊断试剂)。涉及药品：“沙眼衣原体核酸检测试剂盒(PCR-荧光法)”、“副流感病毒核酸检测试剂盒(荧光PCR法)”。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496395.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IEIH","AGNG","LNGR","159883","GDOC","BK0028","RSPH","002022","BK0239","BK1574","MEDX","BK0046","LGHT","BK1583","HART","BK1100","09996","BK0188","PTH","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667641986","title":"董事長兼總裁吳豫生增持同源康醫藥-B(02410.HK)40萬股 每股作價約2.82港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667641986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667641986?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:07","pubTimestamp":1789470429,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","BK1574","02410","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667964132","title":"創新藥「一日遊」？華寶基金藥ETF、港股通創新藥ETF雙雙回調！基本面仍有支撐：數據讀出+出海邏輯持續驗證","url":"https://stock-news.laohu8.com/highlight/detail?id=2667964132","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667964132?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 19:04","pubTimestamp":1789470240,"startTime":"0","endTime":"0","summary":"逆市大涨之后，9月15日，A+H创新药短线迎来回调，药ETF华宝、港股通创新药ETF华宝标的指数分别收跌0.8%、1.48%。创新药龙头数据读出。出海逻辑持续验证。逢跌埋伏创新药，关注两大投资工具：港股通创新药ETF华宝：紧密跟踪恒生港股通创新药精选指数，100%布局创新药研发类公司，前十大权重股占比超七成，龙头属性突出，底层资产是港股，高弹性、T+0。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-15/doc-inirxhzq8476737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","BK4550","FDN","IBBQ","LNGR","MEDX","FLHK","159316","BK4588","159992","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667467806","title":"全球首個！上海交大教授創辦，AI製藥拿下C1輪融資","url":"https://stock-news.laohu8.com/highlight/detail?id=2667467806","media":"智药局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667467806?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 18:00","pubTimestamp":1789466400,"startTime":"0","endTime":"0","summary":"今日，宇道生物宣布完成数千万美元的C1轮融资。一家专攻难成药靶点的公司宇道生物是国内最早依托“AI+物理”双轮驱动技术，系统性攻克难成药靶标药物研发的行业龙头企业之一，由AI+变构领域全球顶级科学家、上海交通大学特聘教授张健创立。技术方面，公司搭建了全球规模领先的蛋白构象调控数据库AlloMatrix，并自研拥有自主知识产权的AI+物理计算平台AlloStar。本轮融资主要用于加速AI+物理计算平台迭代和核心管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-15/doc-inirxats8585013.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VTHR","01477","CHAT","ARTY","AGIX","BK1191","BK1574","QTOC","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667664559","title":"勁方醫藥-B(02595)9月15日斥資129.56萬港元回購5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667664559","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667664559?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 17:50","pubTimestamp":1789465841,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月15日，该公司斥资129.56万港元回购5万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496282.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02595","BK1515","159938","09939","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667643414","title":"歸創通橋(02190)9月15日耗資約112.75萬港元回購5.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643414","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643414?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 17:36","pubTimestamp":1789465011,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)公布，2026年9月15日耗资约112.75万港元回购5.5万股股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","BK1100","BK1587","02190"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667170648","title":"交銀國際：維持德琪醫藥(06996.HK)「買入」評級 目標價10港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667170648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667170648?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:55","pubTimestamp":1789462559,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1583","BK1574","06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667648612","title":"可以多活8.2個月！國產雙抗挑戰全球腫瘤「藥王」總生存期勝出","url":"https://stock-news.laohu8.com/highlight/detail?id=2667648612","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667648612?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 16:46","pubTimestamp":1789461960,"startTime":"0","endTime":"0","summary":"2026年世界肺癌大会，对于国产创新药而言，不只是“被看见”，更要回答一个硬核的问题：到底能不能让患者活得更久。继翰森制药ADC药物刷新全球小细胞肺癌二线治疗最长总生存期（OS）纪录外，另外一款国产创新药挑战全球肿瘤“药王”总生存期的数据也揭晓了。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153874734252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153874734252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2461242641.AUD","LU1934455863.HKD","LU1989772923.USD","KURE","LU2023250843.SGD","IE00B4R5TH58.HKD","LU2476274720.SGD","LU0823416689.USD","LU1961090484.USD","SG9999002232.USD","09926","LU0477156953.USD","LU0348783233.USD","SG9999001176.SGD","LU0965508806.USD","LU0348825331.USD","LU2361044865.SGD","LU2399975544.HKD","LU2360032135.SGD","SG9999002224.SGD","BK4533","IE00BBT3K403.USD","LU0289739343.SGD","LU1989771016.USD","LU0208291251.USD","LU1941712348.USD","FHLC","LU0070302665.USD","LU0634319403.HKD","SG9999001440.SGD","LU1032466523.USD","MRK","GDOC","XLV","LU0348735423.USD","VHT","IE00BFTCPJ56.SGD","LU2488822045.USD","LU2778985437.USD","LU1116320901.HKD","IE00BLSP4452.SGD","BK4559","LU0098860793.USD","LU0122379950.USD","LU1023059063.AUD","PPH","LU1116320737.USD","LU0472753341.HKD","LU1066051225.USD","IE00B543WZ88.USD","LU0980610538.SGD","LU0130517989.USD","IE00BLSP4239.USD","LU1093756168.USD","LU1035773651.USD","LU2125154778.USD","LU2125909247.SGD","LU0417516902.SGD","LU0511384066.AUD","LU1162221912.USD","IE00B2B36J28.USD","LU1934455277.USD","LU0861579265.USD","RXL","BK4550","LU0203347892.USD","LU1066053197.SGD","IE00BJJMRZ35.SGD","LU0432979614.USD","LU0124676726.USD","LU1571399168.USD","BMED","BK4585","LU1061106388.HKD","LU1989772840.SGD","IE00BSNM7G36.USD","LU1720050803.USD","IE00BPRC5H50.USD","LU0130102774.USD","LU0238689110.USD","LU1093756325.SGD","LU0868494617.USD","LU0868494708.USD","LU2125154935.USD","LU0289961442.SGD","LU0942090050.USD","SG9999001176.USD","LU0265550359.USD","PAWZ","IHE","IE0002141913.USD","LU0006306889.USD","LU0689626769.HKD","LU1923622614.USD","BK4516","LU0069063385.USD","LU0648001328.SGD","LU2361045086.USD","LU1585245621.USD","LU0965509010.AUD","LU1066051498.USD","LU0965509101.SGD","HRTS","LU0320765489.SGD","LU1941712264.USD","LU0348784397.USD","LU2023250504.SGD","LU0266013472.USD","LU1929549753.HKD","SG9999014559.SGD","LU2491050154.USD","LU0348767384.USD","BK4007","LU0106261372.USD","LU0417516738.SGD","LU0234572021.USD","LU0561508036.HKD","LU2491050071.SGD","SG9999014567.USD","LU1037948897.HKD","IXJ","LU0057025933.USD","LU1794554557.SGD","LU1983299246.USD","LU2361044949.HKD","LU0348766576.USD","IE000M9KFDE8.USD","LU2089984988.USD","LU1974910355.USD","LU0348827113.USD","LU2125909593.SGD","TRUH","JDOC","LU1066051811.HKD","LU2357627491.SGD","LU0320765646.SGD","SG9999015358.SGD","LU2491049909.HKD","LU1430594728.SGD","LU1201861249.SGD","IE00B1BXHZ80.USD","LU0211331839.USD","LU1291159041.SGD","LU2433249047.HKD","LU1917777945.USD","FTXH","LU0965509283.SGD","LU2468319806.SGD","LU2112291526.USD","LU0265550946.USD","IE00BJT1NW94.SGD","LU2324357040.USD","BK1574","LU1037948541.HKD","LU2106854487.HKD","BK1161","IE0009355771.USD","LU0985320562.USD","LU1057294990.SGD","LU0058720904.USD","LU1934455194.USD","SGXZ57979304.SGD","IYH","LU0289739699.SGD","LU0417516571.SGD","LU0203345920.USD","BK4534","LU2476274308.USD","LU0859254822.USD","LU1699723380.USD","BK4588","SG9999014575.USD","SG9999013999.USD","IE00B5MMRT66.SGD","SG9999015341.SGD","SG9999014542.SGD","LU1069347547.HKD","LU0540923850.HKD","IE00BN8TJ469.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667526611","title":"港股異動 | 心瑋醫療-B(06609)升逾5% 上半年缺血性卒中業務收入持續穩增 公司穩步推進A股IPO進程","url":"https://stock-news.laohu8.com/highlight/detail?id=2667526611","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667526611?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 14:15","pubTimestamp":1789452903,"startTime":"0","endTime":"0","summary":"2026年上半年，公司缺血性卒中业务收入继续保持稳定增长。值得关注的是，心玮医疗计划于2026年下半年向上海证券交易所提交首次公开发行A股并在科创板上市的申请，预计拟募集资金规模约5亿元，预计发行比例约15%，并将继续根据公司经营情况及监管要求推进股票回购、现金分红等工作。中信建投表示，公司正稳步推进A股IPO进程，未来有望通过A股IPO上市进一步提升资本市场流动性，加速公司在全球市场的商业化布局。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06609","03130","02827","FRHC","BK4127","82846","BK1100","BK1587","02846","KCAI","BK4585","83188","BK1574","159982","83130","03188","REDS","BK1147","VXUS","KCE","07233","399300","BK4588","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667619385","title":"港股異動 | 禮邦醫藥-B(09637)午後飆升逾17% AP308治療IgA腎病新藥臨床申請獲美國FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667619385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667619385?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 13:36","pubTimestamp":1789450580,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，礼邦医药-B午后飙升逾17%。消息面上，礼邦医药近日宣布，AP308用于治疗IgA肾病的新药临床试验申请近日获美国食品药品监督管理局批准。公司计划于近期启动AP308的首次人体临床试验。AP308的IND获批标志着这一首创新药由临床前研究迈入临床开发阶段。公告指出，IgA肾病是全球最常见的原发性肾小球肾炎，2025年全球患者约950万人，其中中国约510万人，占全球过半。约60%中国患者于确诊后15年内进展至终末期肾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09637","BK1574","09939","159938","VXUS","BK1191","BK1515","BK4585","KCAI","LABU","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667616045","title":"禮邦醫藥－Ｂ(09637)股價顯著上升14.696%，現價港幣$26.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616045","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667616045?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 13:30","pubTimestamp":1789450200,"startTime":"0","endTime":"0","summary":"[上升股]礼邦医药－Ｂ(09637) 股价在下午01:30比前收市价显著上升14.696%，现股价为港币$26.38。至目前为止，今日最高价为$26.38，而最低价为$22.78。总成交量为84.79万股，总成交金额为港币$2.12千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151589/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151589/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["159938","09637","BK1515","BK1161","BK1574","BK1191","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667616501","title":"渠道紅利見頂，主動投研掉隊  工銀瑞信的權益短板誰來補？","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616501","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667616501?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 11:54","pubTimestamp":1789444440,"startTime":"0","endTime":"0","summary":"依托大股东工商银行遍布全国的庞大渠道网络，工银瑞信是国内银行系公募的代表性机构，总管理规模迈上 2.56 万亿元台阶，养老金业务也位居行业前列。当渠道红利逐渐见顶，产品业绩、人才体系、内控治理三重压力接踵而至，这家头部公募正迎来一场绕不开的考验。明星产品深度回撤风格漂移引争议根据工商银行年报披露的工银瑞信经营数据，2025 年全年，公司实现净利润 30.07 亿元，同比增长 42.5%；进入 2026 年上半年，公司增长势头进一步提速。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-15/doc-inirwsee3872484.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667184356","title":"同源康醫藥－Ｂ(02410)股價大幅上升15.635%，現價港幣$3.55","url":"https://stock-news.laohu8.com/highlight/detail?id=2667184356","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667184356?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 10:44","pubTimestamp":1789440240,"startTime":"0","endTime":"0","summary":"[上升股]同源康医药－Ｂ(02410) 股价在上午10:43比前收市价大幅上升15.635%，现股价为港币$3.55。至目前为止，今日最高价为$3.55，而最低价为$3.175。总成交量为231.15万股，总成交金额为港币$775.694万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152547499_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151343/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609151343/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09939","02410","BK1574","BK1161","159938","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690153","title":"浙商證券：醫療器械子版塊多因素交織 低值耗材板塊表現亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690153","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690153?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 10:06","pubTimestamp":1789437973,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，浙商证券发布研报称，展望2026年下半年，该行认为医疗器械子版块外部发展环境和内部发展逻辑略有不同，多因素交织。其他子版块净利润受外汇损益等因素较大营运能力：家用医疗板块、IVD、低值耗材板块应收账款周转率均有提升，考虑到存货周转率和资产周转率维持稳定，IVD和低值耗材板块ROE有所提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK0276","LNGR","MEDX","GDOC","PTH","601878","LGHT","HART","BK1100","159883","BK1583","IEIH","MDEV","AGNG","09996","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667690691","title":"港股異動 | 同源康醫藥-B(02410)漲逾10% 大股東增持提振市場信心 此前核心品種已順利獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2667690691","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667690691?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 10:02","pubTimestamp":1789437751,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B今早震荡走高，截至发稿，涨10.1%，报3.38港元，成交额389.48万港元。此外，今年8月底，同源康医药披露其核心品种顺利获批，公司自主研发的新一代EGFR-TKI创新药甲磺酸氘申艾替尼片已获得NMPA批准，在国内附条件上市，适应症为具有EGFR 19DEL或L858R置换突变，并伴有CNS转移的局部晚期或转移性非小细胞肺癌成人患者的一线治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496014.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","BK4585","BK4588","KCAI","BK1574","VXUS","09939","02410","159938"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":1,"totalSize":348,"code":"91000000","status":"200"}]}}